These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12475840)

  • 1. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD.
    Duranti R; Filippelli M; Bianchi R; Romagnoli I; Pellegrino R; Brusasco V; Scano G
    Chest; 2002 Dec; 122(6):2009-14. PubMed ID: 12475840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium and simplified detection of dynamic hyperinflation.
    Gelb AF; Taylor CF; McClean PA; Shinar CM; Rodrigues MT; Gutierrez CA; Chapman KR; Zamel N
    Chest; 2007 Mar; 131(3):690-695. PubMed ID: 17356081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD.
    Aliverti A; Rodger K; Dellacà RL; Stevenson N; Lo Mauro A; Pedotti A; Calverley PM
    Thorax; 2005 Nov; 60(11):916-24. PubMed ID: 15994253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung hyperinflation and flow limitation in chronic airway obstruction.
    Pellegrino R; Brusasco V
    Eur Respir J; 1997 Mar; 10(3):543-9. PubMed ID: 9072982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity.
    Deesomchok A; Webb KA; Forkert L; Lam YM; Ofir D; Jensen D; O'Donnell DE
    COPD; 2010 Dec; 7(6):428-37. PubMed ID: 21166631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.
    Belman MJ; Botnick WC; Shin JW
    Am J Respir Crit Care Med; 1996 Mar; 153(3):967-75. PubMed ID: 8630581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchodilator response of advanced lung function parameters depending on COPD severity.
    Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inspiratory drive is related to dynamic pulmonary hyperinflation in COPD patients.
    Gatta D; Fredi M; Aliprandi G; Pini L; Tantucci C
    Int J Chron Obstruct Pulmon Dis; 2013; 8():169-73. PubMed ID: 23569371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation.
    Newton MF; O'Donnell DE; Forkert L
    Chest; 2002 Apr; 121(4):1042-50. PubMed ID: 11948031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD.
    Cazzola M; Rogliani P; Curradi G; Segreti A; Ciaprini C; Pezzuto G; Saltini C
    Pulm Pharmacol Ther; 2009 Dec; 22(6):522-5. PubMed ID: 19481169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spirometric reversibility to salbutamol in chronic obstructive pulmonary disease (COPD). Differential effects on FEV1 and on lung volumes].
    Manríquez J; Díaz O; Borzone G; Lisboa C
    Rev Med Chil; 2004 Jul; 132(7):787-93. PubMed ID: 15379324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
    Celli B; ZuWallack R; Wang S; Kesten S
    Chest; 2003 Nov; 124(5):1743-8. PubMed ID: 14605043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
    Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M
    Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of bronchodilator responses in patients with "irreversible" emphysema.
    O'Donnell DE; Forkert L; Webb KA
    Eur Respir J; 2001 Dec; 18(6):914-20. PubMed ID: 11829096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease.
    Hadcroft J; Calverley PM
    Thorax; 2001 Sep; 56(9):713-20. PubMed ID: 11514693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
    Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the clinical value of lung volumes?
    Ruppel GL
    Respir Care; 2012 Jan; 57(1):26-35; discussion 35-8. PubMed ID: 22222123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal lung volume changes in patients with chronic obstructive pulmonary disease.
    Lee JS; Kim SO; Seo JB; Lee JH; Kim EK; Kim TH; Kim WJ; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Lee SW; Huh JW; Oh YM; Lee SD
    Lung; 2013 Aug; 191(4):405-12. PubMed ID: 23715996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD.
    Dellacà RL; Pompilio PP; Walker PP; Duffy N; Pedotti A; Calverley PM
    Eur Respir J; 2009 Jun; 33(6):1329-37. PubMed ID: 19164347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not all measures of hyperinflation are created equal: lung structure and clinical correlates of gas trapping and hyperexpansion in COPD: the Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study.
    Smith BM; Hoffman EA; Basner RC; Kawut SM; Kalhan R; Barr RG
    Chest; 2014 Jun; 145(6):1305-1315. PubMed ID: 24481056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.